Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Mineralys Therapeutics (MLYS) reported Q2 2026 earnings, highlighting a net loss of $241.1 million due to royalty repurchase obligations. Key financial activities included a $150 million equity offering and a $100 million tranche from a $500 million loan. The company is preparing for the FDA's PDUFA date for lorundrostat, a hypertension treatment, with commercial launch plans and payer discussions underway. Management expressed optimism about the regulatory review and market potential.

Mineralys Therapeutics reported Q2 2026 updates on lorundrostat. The company said it repurchased future royalties from Mitsubishi Tanabe for $200 million, secured a $500 million senior secured term loan, and completed a $150 million equity offering. R&D rose to $221.4 million. It cited LAUNCH-HTN results and targeted a Dec. 22, 2026 PDUFA, with FDA discussions in Oct-Nov 2026.

Mineralys Therapeutics (MLYS) discussed exploratory proteomic biomarker results from its Launch-HTN and Advance-HTN trials at ENDO 2026, with management saying lorundrostat was linked to reductions in heart-failure risk biomarkers. The company expects FDA discussions to intensify near the October-November PDUFA window, and outlined U.S. payer and physician outreach ahead of a December PDUFA launch. Q2 cash was $661.4M; net loss was $241.1M.

Investing.com reports Mineralys Therapeutics (MLYS) shares fell 4.9% in after-hours after posting a Q2 2026 per-share loss of $2.85 versus a $2.63 analyst consensus. The loss followed a rise in operating costs, including $221.4 million R&D and a $200 million upfront payment to Tanabe for lorundrostat royalty buyout. FDA PDUFA is Dec. 22, 2026.

Mineralys Therapeutics, Inc. (MLYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update – PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine e

Mineralys Therapeutics (MLYS) revised its deal with Tanabe Pharma to obtain full worldwide rights to lorundrostat without future royalties. MLYS will pay $200M upfront and up to $365M based on commercial targets, and secured a staged loan up to $500M from Pharmakon Advisors tied to FDA approval and sales milestones. Goldman Sachs reiterated Buy and set a $42 target.